Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
BASEL, Switzerland, March 20, 2026 Novartis announced a major strategic acquisition to strengthen its oncology portfolio, agreeing to acquire...
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
